Sort
15,273 grants matching “antimicrobial resistance”
Interaction of Pseudomonas Aeroginosa with the Mucosal Barrier
$110,539Joanne N. Engel · University Of California, San Francisco · P01 · FY2009 · AI
A Nanofibrous Bioactive Prosthetic Sewing Cuff
$110,528Matthew Douglas Phaneuf · Biosurfaces · R41 · FY2009 · HL
Identifying Risk Factors for Antibiotic Resistance via Integration of Epidemiology and Metagenomics
$110,387Jessica Rhea Galloway-Pena · University Of Tx Md Anderson Can Ctr · K01 · FY2019 · AI
Identifying Risk Factors for Antibiotic Resistance via Integration of Epidemiology and Metagenomics
$110,387Jessica Rhea Galloway-Pena · University Of Tx Md Anderson Can Ctr · K01 · FY2020 · AI
NOVEL MARINE ANTIMICROBIAL LIPIDS
$110,273University Of Puerto Rico Rio Piedras · S06 · FY2001 · GM
NOVEL MARINE ANTIMICROBIAL LIPIDS
$110,273University Of Puerto Rico Rio Piedras · S06 · FY2000 · GM
Determining the subcellular and molecular players in neutrophil trogocytic killing of the sexually-transmitted parasite Trichomonas vaginalis
$110,250Frances Mercer · California State Poly U Pomona · SC3 · FY2021 · GM
Determining the subcellular and molecular players in neutrophil trogocytic killing of the sexually-transmitted parasite Trichomonas vaginalis
$110,250Frances Mercer · California State Poly U Pomona · SC3 · FY2020 · GM
Determining the subcellular and molecular players in neutrophil trogocytic killing of the sexually-transmitted parasite Trichomonas vaginalis
$110,250Frances Mercer · California State Poly U Pomona · SC3 · FY2022 · GM
Determining the subcellular and molecular players in neutrophil trogocytic killing of the sexually-transmitted parasite Trichomonas vaginalis
$110,250Frances Mercer · California State Poly U Pomona · SC3 · FY2023 · GM
S. mutans GTF - a novel target for dental caries prevention
$110,250Sadanandan E. Velu · University Of Alabama At Birmingham · R03 · FY2016 · DE
S. mutans GTF - a novel target for dental caries prevention
$110,250Sadanandan E. Velu · University Of Alabama At Birmingham · R03 · FY2015 · DE
Control of heterogeneous microbial communities using model-based multi-objective optimization
$110,182Reinhard Laubenbacher · University Of Connecticut Sch Of Med/Dnt · R01 · FY2018 · GM
New Point of Care System for Burn Wound Treatment
$110,040Lynntech, Inc. · R43 · FY2003 · GM
Molecular Mechanisms of Clostridium difficile Resistance to Innate Host Defenses
$110,009Shonna M. McBride · Tufts University Boston · K01 · FY2011 · DK
Sustainable one health research training capacity: Molecular epidemiology of zoonotic foodborne and waterborne pathogens in Eastern Africa
$110,000Wondwossen A. Gebreyes · Ohio State University · D43 · FY2020 · TW
Blocking Cationic Antimicrobial Peptide-Resistance in Pseudomonas aeruginosa
$109,875Laura C. Miller Conrad · San Jose State University · SC3 · FY2024 · GM
Blocking Cationic Antimicrobial Peptide-Resistance in Pseudomonas aeruginosa
$109,875Laura C. Miller Conrad · San Jose State University · SC3 · FY2023 · GM
Developing an in vivo infectious disease training program at the University of Cape Town
$109,774William Horsnell · University Of Cape Town · D71 · FY2023 · TW
Generation of a Monoclonal Antibody Agonist to Toll-Like Receptor 5
$109,719Olga B Chernova · Buffalo Biolabs, Llc · R43 · FY2009 · CA
DETERMINE EFFECT OF ANTIMICROBIAL OLIGOMERS ON BACTERIAL AND EUKARYOTIC CELLS
$109,617Annelise Barron · University Of California, San Francisco · P41 · FY2010 · RR
SALMONELLA ANTIMICROBIAL PEPTIDE RESISTANCE
$109,550University Of Texas Hlth Sci Ctr San Ant · R29 · FY2002 · AI
PLASMID MEDIATED QUINOLONE RESISTANCE
$109,442Lahey Clinic · R01 · FY2000 · AI
Interaction of Pseudomonas Aeroginosa with the Mucosal Barrier
$109,333Joanne N. Engel · University Of California, San Francisco · P01 · FY2010 · AI
**AWARDS ISSUED PRIOR TO JANUARY 20, 2025, WERE FUNDED UNDER PREVIOUS ADMINISTRATIONS AND MAY NOT REFLECT THE PRIORITIES AND POLICIES OF THE CURRENT ADMINISTRATION.** THE AVIAN PATHOGENICE. COLI(APEC) IS ONE OF THE MAJOR BACTERIAL PATHOGENS OF SIGNIFICANT CONCERNS TO THE US AND GLOBAL POULTRY INDUSTRY.APEC CAUSES WIDE RANGE OF LOCALIZED AND SYSTEMIC INFECTIONS IN POULTRY, INCLUDING YOLK SAC INFECTION, OMPHALITIS, RESPIRATORY TRACT INFECTION, SWOLLEN HEAD SYNDROME, SEPTICEMIA, POLYSEROSITIS, COLIGRANULOMA, ENTERITIS, CELLULITIS AND SALPHINGITIS; COLLECTIVELY REFERRED AS COLIBACILLOSIS.COLIBACILLOSIS CULMINATES IN MULTI-MILLION DOLLARS ANNUAL LOSSES TO ALL THE FACETS OF POULTRY INDUSTRY AND REMAINS AS A SERIOUS IMPEDIMENT TO THE SUSTAINABLE POULTRY PRODUCTION WORLDWIDE. CURRENT CONTROL METHODS USING ANTIBIOTIC MEDICATION AND VACCINATION HAVE LIMITATION AS APEC IS RESISTANCE TO MULTIPLE ANTIBIOTICS AND THE AVAILABLE VACCINES FAIL TO CONFER PROTECTION AGAINST DIVERSE AND HETEROLOGOUS APEC SEROTYPES. THEREFORE, DEVELOPING NEW AND POTENT ANTI-APEC THERAPEUTICS AS AN ALTERNATIVE TO CURRENT CONTROL MEASURES ARE URGENTLY NEEDED. WE PREVIOUSLY IDENTIFIED PROBIOTIC-DERIVED ANTIMICROBIAL PEPTIDES (P-1 AND P-2) THAT IN SMALL PILOT STUDIES REDUCED THE COLONIZATION OF APEC IN CECUM AND INTERNAL ORGANS OF CHICKENS. THESE PEPTIDES ARE HEAT AND PROTEOLYSIS RESISTANT, EFFECTIVE AGAINST DIVERSE APEC SEROTYPES, ANTIBIOTIC-RESISTANT APEC STRAINS AND AGAINST BIOFILM-PROTECTED APEC. FURTHER, THESE PEPTIDES FUNCTION BY DISRUPTING OUTER MEMBRANE OF APEC, A MECHANISM TO WHICH RESISTANCE IS LESS LIKELY TO OCCUR. HERE, WE PLAN TO EVALUATE THE EFFICACY, SAFETY AND APPLICABILITY OF IDENTIFIED ANTI-APEC PEPTIDES (P-1 AND P-2) IN DRINKING WATER OF CHICKENS AND TO ELUCIDATE THEIR MECHANISM(S) OF ACTION. OUR OVERARCHING GOAL IS TO DEVELOP THESE PEPTIDES AS NEW ANTI-APEC THERAPEUTICS AS AN ALTERNATIVE TO ANTIBIOTICS. WE EXPECT THAT THESE PEPTIDES WILL PROVIDE A NOVEL THERAPEUTIC SOLUTION TO ENHANCE THE CONTROL OF APEC INFECTIONS IN POULTRY, WHICH WILL CONSEQUENTLY PROMOTE THE SUSTAINABLE POULTRY PRODUCTION AND BENEFIT THE PUBLIC HEALTH.
$109,162Ohio State University, The · · FY2022 · National Institute of Food and Agriculture